Pharma & Biotech
You will receive alerts when there are new announcements on Oncimmune
Only registered members can use this feature.
Oncimmune's range of diagnostic tests profile the body’s immune response to detect evidence of the body’s natural response to cancer, which can detect cancer on average four years earlier than standard clinical diagnosis.
The City broker's forecasts are unchanged, while it has reiterated its 150p share price target
© Proactive 2021.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.